Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2351 to 2360 of 2733 total matches.

Rasburicase (Elitek) for Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002  (Issue 1143)
* Allopurinol generic 150-300 mg PO $ 1.82 Zyloprim (Prometheus) 2.20 Aloprim (Nabi) 200 mg/m 2 IV 1290.00 ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Med Lett Drugs Ther. 2002 Nov 11;44(1143):96-7 |  Show IntroductionHide Introduction

Drug-eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
(SIRIUS) randomized 1,101 patients with previously untreated coronary lesions, including some with longer ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):23-4 |  Show IntroductionHide Introduction

Cinacalcet (Sensipar)

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2004  (Issue 1192)
concentrations. 1 CLINICAL STUDIES — Three placebo-controlled clinical trials in patients ...
Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma.
Med Lett Drugs Ther. 2004 Sep 20;46(1192):80 |  Show IntroductionHide Introduction

Clarification: Hand Hygiene and CDAD

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007  (Issue 1253)
will not eradicate C. difficile spores.” 1 One reader pointed out that alcoholbased products do eradicate some C ...
In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.”1 One reader pointed out that alcoholbased products do eradicate some C. difficile spores and have been invaluable against other pathogens.In an unpublished study available as an abstract, both...
Med Lett Drugs Ther. 2007 Jan 29;49(1253):9 |  Show IntroductionHide Introduction

In Brief: Toxicity of Gadolinium-Based Contrast Agents

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
, that gadolinium-based agents may also be nephrotoxic. 1 One patient who developed acute renal failure after use ...
Gadolinium-based contrast agents, which are used mainly for magnetic resonance imaging and angiography, were first introduced partly because of the discovery in the 1990’s that iodine-based contrast agents could cause nephrotoxicity and acute renal failure. Some recent reports have suggested, however, that gadolinium-based agents may also be nephrotoxic.1 One patient who developed acute renal failure after use of gadolinium-based contrast had a renal biopsy that showed acute tubular injury.2Moreover, after exposure to gadolinium-based contrast, some patients with severe renal insufficiency,...
Med Lett Drugs Ther. 2007 Jun 4;49(1262):45 |  Show IntroductionHide Introduction

Addendum: Warfarin-Acetaminophen Interaction

   
The Medical Letter on Drugs and Therapeutics • Jun 16, 2008  (Issue 1288)
Interactions” 1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase ...
A reader expressed disappointment that our recent listing of “Some Warfarin Drug Interactions”1 did not include acetaminophen. Perhaps it should have. Acetaminophen can increase the anticoagulant effect of warfarin, particularly with continued use, but it does so inconsistently. The mechanism of this interaction has not been established, but may be related to an acetaminophen metabolite inhibiting vitamin K-epoxide reductase, the target for warfarin’s anticoagulant effect.2Patient susceptibility varies, possibly on a genetic basis; occasional use of acetaminophen generally has little or...
Med Lett Drugs Ther. 2008 Jun 16;50(1288):45 |  Show IntroductionHide Introduction

Varenicline (Chantix) Warnings: Risk Versus Benefit

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008  (Issue 1290)
, 1 but the FDA has added a warning to the package insert about neuropsychiatric symptoms ...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53 |  Show IntroductionHide Introduction

ECGs Before Stimulants in Children

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008  (Issue 1291)
being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). 1 ...
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
Med Lett Drugs Ther. 2008 Jul 28;50(1291):60 |  Show IntroductionHide Introduction

In Brief: Injectable Paliperidone Palmitate for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
. An extendedrelease oral formulation (Invega) has been available since 2006. 1 Long-acting injections ...
Paliperidone palmitate (Invega Sustenna – Ortho-McNeil Janssen) has been approved by the FDA as a once-monthly injection for acute and maintenance treatment of schizophrenia in adults. An extended-release oral formulation (Invega) has been available since 2006.1 Long-acting injections of antipsychotic drugs typically are used to treat patients who cannot adhere to an oral regimen.2,3 Paliperidone is the primary active metabolite of risperidone (Risperdal), which is also available as a long-acting (every 2 weeks) injection. It is unclear whether either risperidone or paliperidone is a better...
Med Lett Drugs Ther. 2009 Nov 2;51(1324):88 |  Show IntroductionHide Introduction

Belatacept (Nulojix) for Prevention of Renal Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011  (Issue 1379)
higher in those taking belatacept.1 After 3 years, 206 (91%) of 226 patients taking LI belatacept were ...
The FDA has approved belatacept (bel at´ a sept; Nulojix – Bristol-Myers Squibb) for prevention of organ rejection in adult patients receiving a kidney transplant.
Med Lett Drugs Ther. 2011 Dec 12;53(1379):98-9 |  Show IntroductionHide Introduction